EMA/788682/2016

European Medicines Agency decision

P/0352/2016

of 2 December 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for betrixaban (EMEA-001834-PIP02-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0352/2016

of 2 December 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for betrixaban (EMEA-001834-PIP02-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Portola Pharma UK Limited on 8 August 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 November 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for betrixaban, capsule, hard, age appropriate formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for betrixaban, capsule, hard, age appropriate formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Portola Pharma UK Limited, 209 Tower Bridge Business Centre, 46-48 East Smithfield, E1W 1AW – London, United Kingdom.

EMA/PDCO/599236/2016 Corr
London, 11 November 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-001834-PIP02-16

Scope of the application

Active substance(s):

Betrixaban

Condition(s):

Prevention of venous thromboembolism

Pharmaceutical form(s):

Capsule, hard

Age appropriate formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Portola Pharma UK Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Portola Pharma UK Limited submitted for agreement to the European Medicines Agency on 8 August 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 13 September 2016.

Supplementary information was provided by the applicant on 28 October 2016. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Prevention of venous thromboembolism

2.1.1. Indication(s) targeted by the PIP

Prophylaxis of venous thromboembolism in paediatric patients

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Age appropriate formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate oral liquid dosage form.
Non-clinical studies	1	Study 2 Study with rats to investigate potential adverse effects on the kidneys, liver, bladder and eye.
Clinical studies	4	Study 3 Single dose PK (pharmacokinetic) study in paediatric patients who completed a course of anticoagulation, from 28 days to less than 18 years old in the fed or fasted state. Study 4 Single arm open label study in paediatric patients from 28 days to less than 18 years old with an acute medical or surgical illness who require prophylaxis of venous thromboembolism with low intensity anticoagulation.

		Study 5 Single arm, open label, PK, safety and activity study in term and preterm neonates (less than 28 days) with an umbilical venous or umbilical arterial catheter who require prophylaxis of venous thromboembolism with low intensity anticoagulation. Study 6 Open label, single dose trial to evaluate PK/PD of andexanet alfa in children administered at the end of their treatment with betrixaban. *This study is the same as Study 6 in EMEA-001902-PIP01-15, P/0199/2016 of July 2016 and subsequent modifications thereof.*
Extrapolation, modelling and simulation studies	2	Study 7 Modelling and simulation sub-study 1 (as part of Study 3, Part 1 and Part 2) Study 8 Modelling and simulation sub-study 2 (as part of Study 3, Part 1 and Part 2)
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2024.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes